Could a drug combo stop smoldering myeloma in its tracks?
NCT ID NCT04776395
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests iberdomide, an immunotherapy drug, alone or with dexamethasone in 68 people with intermediate- or high-risk smoldering multiple myeloma. The goal is to see if the treatment can shrink or control the cancer cells and delay progression to active myeloma. Participants will be monitored with blood tests, urine tests, and bone marrow biopsies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iberdomide and dexamethasone
What this could lead to
If successful, this could offer a new treatment option to delay or prevent smoldering myeloma from becoming active cancer.
What could go wrong
This is an early-phase trial with only 68 participants, so results may not apply broadly. Side effects from the drugs could also limit tolerability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University Hospital/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact